Five years until a rare disease has been diagnosed properly? – Global commission wants to speed diagnosis
About the author
Prof. Matthias P. Schönermark, M.D., Ph.D.
Founder and Managing Director
Founder and Managing Director
Fon: +49 511 64 68 14 – 0
Fax: +49 511 64 68 14 18
Fax: +49 511 64 68 14 18
The strategic alliance of the companies Shire, Microsoft and EURORDIS-Rare Diseases Europe forms a multidisciplinary commission of experts and creative thinkers. The commissions’ goal is to develop a roadmap with recommended actions which address core barriers preventing timely diagnosis until January 2019. The focus is on three interest groups, for which the following questions should be answered: How can physicians enlarge their knowledge of rare diseases? How can patients and their families be empowered? How can politics expand their advising actions?
The SKC Beratungsgesellschaft welcomes the foundation of the commission, because with an early diagnosis, exact therapeutic actions can be introduced faster, possibly leading to improved living conditions of the patients. SKC, the leading strategic consultancy for healthcare in Germany, supports and advises pharmaceutical entrepreneurs in the process of market access with the objective to bring the orphan drugs to the German market. Read more about “orphan drugs in Germany” in our Whitepaper.
BY Prof. Matthias P. Schönermark, M.D., Ph.D., managing director and Karolin Priese, MBA
Sources:
Global Rare Disease Commission
Fierce Pharma: Shire CEO sees Microsoft tie-up building momentum for faster rare disease diagnosis